Mariko Gordon, CFA is the Founder, CEO and CIO of Daruma Capital Management, LLC. Ms. Gordon founded Daruma in 1995. Daruma has two investment teams — one that manages two long-only strategies (small-cap and and smid-cap) in New York and one that runs a long/short strategy in Connecticut. All three strategies manage concentrated portfolios. Mariko Gordon began her financial career in 1986 with Manning & Napier’s New York investment team. In 1990 she joined Valenzuela Capital Management as a partner and research director, investing in a similar, concentrated smid-cap approach. Ms. Gordon holds an A.B. in Comparative Literature from Princeton University and is a Chartered Financial Analyst.
We are covering the 19th IRA Sohn Investment Conference produced in partnership with Bloomberg LINK. Make sure you sign up for our free newsletter to ensure you do not miss any updates!
See our full Ira Sohn 2014 coverage here.
Mariko Gordon spoke at the IRA Sohn Investment Conference, also see Blackjack, Cycling and the Power of the One Percent. Below are notes from his presentation.
Highlights from Mariko Gordon’s presentation
Mariko Gordon, the only female presenter at the Ira Sohn Conference, is up now. David Einhorn follows for the grand finale. She is going to pitch three ideas. The first idea is long Electronics for Imaging (EFII)
5:00 $60 EFII price target. EFII likely to start selling ink this year, adding $1 per share in earnings Her “big dream” price is $75. The stock closed closed today at around $39.
Mariko Gordon: Second Idea is long FUL. Mariko Gordon bullish EFII, FUL #SOHN2014 She’ll be live on @CNBCFastMoney today around 5:20 pm ET In terms of FUl, Gordon notes that current CEO is solving issues of cultural, complexity and costs regarding the current company. She believes FUL will be trading at $70-$90 a share in 3 years
5:05: Gordon says that we are past peak in the capes cycle with FUL, which is now at an inflection point in free cash-flow. The stock is currently trading at about $25 a share.
PCRX is Gordon’s final stock idea. Price target for the stock is $150, while Gordon’s ‘dream big’ price target on $PCRX is $250, which is nearly four times the current price of $73 a share. Gordon likes the companies drug Exparel, which lasts up to 72 hrs to relieve post surgical pain, while avoiding the negative side effects of opioid pain relievers.
David Einhorn is up next!
Mariko Gordon, CFA at the Ira Sohn Investment Conference 2014
Mariko Gordon, CFA, Founder and CEO of Daruma Capital shares three of her investment ideas at the Ira Sohn Investment Conference 2014.